PBR Nachrichten

 

The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from The post Sanofi receives FDA approval for Tzield in paediatric diabetes appeared first on Pharmaceutical Business review....

The collaboration aims to implement an agentic platform across MSD's research and development (R&D), commercial, manufacturing and corporate divisions, with Google Cloud engineers working directly with MSD teams The post MSD teams up with Google Cloud on agentic AI transformation appeared first on Pharmaceutical Business review....

The approval covers Bosaya in a 60mg/ml prefilled syringe and Vevzuo in a 120mg/1.7ml (70mg/ml) single-dose vial, both for subcutaneous injection. Denosumab therapies are used to increase bone The post Health Canada approves Biocon's two denosumab biosimilars appeared first on Pharmaceutical Business review....

The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis' gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without suppressing immune The post BioAegis and Prenosis partner for inflammatory disease therapies appeared first on Pharmaceutical Business review....

The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. It could potentially broaden the approved use, The post Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy appeared first on Pharmaceutical Business review....

The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of Aicuris for approximately €780m ($920.7m) earlier this year. The acquisition aligns with Asahi Kasei's The post Asahi Kasei acquires German company Aicuris appeared first on Pharmaceutical Business review....

The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. Subject to customary conditions and anti-trust clearance, the transaction is The post UCB to purchase Neurona and NRTX-1001 for $1.15bn appeared first on Pharmaceutical Business review....

This approval authorises Enflonsia's marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway. Enflonsia is a long-acting monoclonal antibody intended for prevention, providing protection over The post MSD secures EC approval for Enflonsia to prevent infant RSV infection appeared first on Pharmaceutical Business review....

This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by The post Aligos and Xiamen Amoytop sign deal for HBV therapy appeared first on Pharmaceutical Business review....

The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna's MNM technology as a delivery enhancer for therapeutic modalities. Interna's MNM molecules The post Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions appeared first on Pharmaceutical Business review....

The collaboration aims to bridge gaps between data generation and actionable insights in spatial proteomics, as multiplex technologies for imaging advance. Spatial proteomics platforms create intricate tissue data, The post Nucleai and Sirona Dx to provide new proteomics solution for pharma companies appeared first on Pharmaceutical Business review....

This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim's DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with The post Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study appeared first on Pharmaceutical Business review....

The financing will support Adcendo's ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main The post Adcendo secures $75m in Series C funding for ADC development appeared first on Pharmaceutical Business review....

The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. The therapy is anticipated to have a US Food and Drug Administration The post Lilly to acquire CrossBridge Bio for up to $300m appeared first on Pharmaceutical Business review....

The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. FSGS is The post Travere Therapeutics gains FDA approval for sparsentan in FSGS appeared first on Pharmaceutical Business review....

The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. The FDA has scheduled a decision date for 10 October 2026 The post MSD, Daiichi Sankyo's ifinatamab deruxtecan receives FDA priority appeared first on Pharmaceutical Business review....

Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global The post Telix and Regeneron to co-develop radiopharmaceutical therapies appeared first on Pharmaceutical Business review....

The decision affects Replimune's lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial, The post FDA issues complete response letter to Replimune's RP1 for melanoma appeared first on Pharmaceutical Business review....

According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets. C4 Therapeutics will use its TORPEDO platform for The post Roche and C4 Therapeutics to advance degrader-antibody conjugates research appeared first on Pharmaceutical Business review....

Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan & Lee. Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise the The post Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation appeared first on Pharmaceutical Business review....